News from takeda pharmaceutical company limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 05, 2019, 18:28 ET Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the company is issuing a US recall for all doses of...


May 15, 2019, 08:00 ET Takeda Celebrates MPS Awareness Day in Recognition of the Seven Rare MPS Diseases

Be #MPSAware for MPS Awareness Day 2019. Takeda is pleased to announce the return of the annual #MPSAware campaign to coincide with MPS Awareness Day ...


Apr 16, 2019, 12:21 ET 17 de abril - Dia Mundial da Hemofilia

O dia 17 de abril é extremamente importante para a comunidade de mais de 12 mil brasileiros que vivem com hemofilia no país. O Dia Mundial da...


Feb 04, 2019, 07:00 ET Takeda to Highlight Advancements in Rare Lysosomal Storage Disorders at Global Scientific Meeting

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will feature 12 presentations, including 11 posters and...


Jun 03, 2018, 08:30 ET Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the...


Feb 16, 2018, 11:00 ET Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease Patients in Comparative Effectiveness Real-World Data Analysis

New clinical study also provides data for Entyvio® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients...


Jan 05, 2018, 02:00 ET Takeda Announces Intention to Acquire TiGenix

Expands Takeda's Late Stage Pipeline and Leadership in Gastroenterology Acquisition Highlights Deal reinforces Takeda's commitment to patients living ...


Nov 01, 2017, 04:30 ET Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease

New meta-analysis provides a comprehensive view of real-world data and furthers understanding of Entyvio as an important treatment option for...


Oct 16, 2017, 08:00 ET New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients

Takeda Pharmaceutical Company Limited (TSE: 4502), ("Takeda") today announced the presentation of data suggesting early symptomatic improvement in...


Sep 26, 2017, 09:00 ET Takeda Named To 2017 Working Mother "100 Best Companies" For Leadership In Family Benefits And Paid Leave

Working Mother magazine today recognized Takeda Pharmaceuticals as one of the 2017 Working Mother 100 Best Companies for its strong leadership in...


May 08, 2017, 10:30 ET New Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the...


Oct 17, 2016, 02:00 ET Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") is presenting data on the real-world effectiveness and safety of vedolizumab in...


Sep 28, 2016, 03:16 ET Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that two interim reports from the ongoing, open-label GEMINI long-term safety ...


Sep 27, 2016, 08:15 ET Takeda Named To 2016 Working Mother "100 Best Companies" For Leadership In Creating Progressive Programs To Support Working Families

Working Mother magazine today recognized Takeda as one of the 2016 "Working Mother 100 Best Companies" for its outstanding leadership in creating...


Sep 16, 2016, 10:48 ET Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an exploratory analysis of the GEMINI 1 data, evaluating Entyvio...


Aug 02, 2016, 02:00 ET Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the 24-week...


Jul 05, 2016, 02:00 ET Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the companies...


Jun 11, 2016, 01:31 ET EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced the publication of a post-hoc analysis from the global EXAMINE (EXamination...


Jun 08, 2016, 08:29 ET Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced...


Jun 06, 2016, 09:38 ET Takeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions

Takeda Pharmaceuticals Company Limited [TSE: 4502], ("Takeda") will present eight abstracts at the American Diabetes Association's 76th Scientific...


May 23, 2016, 12:33 ET Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the oral presentations of two data analyses: one evaluating the optimal ...


Apr 28, 2016, 01:00 ET Takeda Expands Its Help At Hand Patient Assistance Program in U.S.; Reaches Even More Eligible Patients in the U.S.

Takeda today announced its U.S. Business Unit will expand its patient assistance program to make its prescription drugs available to more eligible...


Nov 13, 2015, 10:18 ET Takeda Receives Back-to-Back Recognition, Named a 2015 Top Chicago Workplace

Takeda announced today that the Chicago Tribune named Takeda's Deerfield campus among Chicago's Top 100 Workplaces in 2015. This is the fourth...


Jul 30, 2015, 10:21 ET Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the study to fulfill the post-marketing commitment and submissions ...


Jul 30, 2015, 02:00 ET Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1%

Guidance for FY2015 confirmed, including Core Earnings and Core EPS Highlights of Q1 results Underlying revenue +6.1% year-to-year (reported revenue...